We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Orl6.0
Orlistat Research
Mostly mechanism / observational
23 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Orlistat studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 892 participants.
Based on 23 studies · 9 meta-analyses · 4 RCTs · 22,955 total participants
Confidence
High confidence
By outcome
Weight managementAbout 2.6–2.9 kg more weight loss than placebo at one year; 44% of users reach ≥5% body-weight loss vs 23% on placebo · 4-12 weeks
Mostly mechanism / observational17 studies
Glucose & metabolicIn obese type 2 diabetes on sulfonylureas, significant HbA1c and fasting-glucose reduction with sulfonylurea dose reductions · 3-6 months · Lower total and LDL cholesterol, lower fasting insulin, and a 37.3% relative reduction in new type 2 diabetes over 4 years — but only in those with impaired glucose tolerance at baseline, not across obese adults generally · 6-12 months
Mostly mechanism / observational8 studies
Cholesterol & lipids
Mostly mechanism / observational6 studies
Safety profile
Mostly mechanism / observational5 studies
Women's health
Mostly mechanism / observational3 studies
Heart & blood pressure
Too few graded studies2 studies
Men's vitality
Too few graded studies2 studies
Therapeutic & clinical
Too few graded studies2 studies
4 more outcomes with fewer studies not shown.
Active research area
11 studies in the last 5 years · Latest meta-analysis: 2026
199820122026
1RCTn=3,305 · very large study2004
In plain English: After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = 0.0032).
Torgerson, Hauptman, Boldrin, Sjöström · Diabetes Care (2004)
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Cumulative 4-year diabetes incidence 6.2% with orlistat vs 9.0% with placebo — a 37.3% relative risk reduction (P = 0.0032)
Mean 4-year weight loss 5.8 kg with orlistat vs 3.0 kg with placebo (P < 0.001); with baseline-carried-forward for dropouts, 3.6 vs 1.4 kg (P < 0.001)
In plain English: During the first year orlistat-treated subjects lost more weight (mean ± SEM, 8.76±0.37 kg) than placebo-treated subjects (5.81±0.67 kg) (P<.001).
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Year 1: 8.76 ± 0.37 kg weight loss with orlistat 120 mg three times daily vs 5.81 ± 0.67 kg with placebo (P<.001)
Year 2 regain: 3.2 kg (35.2% regain) on orlistat 120 mg tid vs 4.26 kg (51.3%) on 60 mg tid vs 5.63 kg (63.4%) on placebo (P<.001) — the dose comparison behind the 120 mg Rx vs 60 mg OTC strengths
In plain English: No significant short-term impact on TG was observed, though a modest reduction may emerge with prolonged use.
Khodadadiyan A, Khazraei Y, Kamali M, Kolaei K, Aminzadeh P, Yazdanpanah G, Shams A, Feili M, Ghaffari M, Hosseini M, Bazrafshan M, Drissi HB, Arzhangzadeh A. · Journal of obesity (2026)
Orlistat reduced body mass index (BMI) (SMD [95% CI]: -0.30 [-0.58, -0.03], p value (heterogeneity) = 0.026), and also it was associated with a decrease in high-density lipoprotein cholesterol (SMD (95% CI): -0.31 [-0.48, -0.13], p value (heterogeneity) = 0.436).
The secondary analysis demonstrated that follow-up duration accounted for 30% of TG heterogeneity, suggesting a small but significant decline in orlistat's TG-lowering effect over time (slope: -0.1239; 95% CI: -0.2355, -0.0123; p value = 0.0295).
Evidence for reductions in TG and WC is uncertain: the primary meta-analysis showed no statistically significant effects, whereas trim-and-fill sensitivity analysis suggested potential reductions.
In plain English: Further randomized controlled trials are necessary to ascertain its long-term impact on prognosis.
Zhang L, Meng C, Zhang F, Jia X, Xie J, Zhu Y, Zhou X, Liu P. · Journal of pediatric endocrinology & metabolism : JPEM (2025)
The orlistat group reduced BMI compared to placebo in the short term (MD=-0.73, 95 % CI: -1.44 to -0.02, p=0.04, I 2 =73 %) but appeared to have little effect in the long term (MD=-1.72, 95%CI: -3.55 to 0.12, p=0.07, I 2 =84 %).
Conclusions Orlistat has been linked to alter lipid levels in obese or overweight children.
However, the evidence regarding its efficacy in reducing BMI is inconclusive, with inconsistent findings across short and long-term studies.
In plain English: Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg).
Rucker, Padwal, Li, Curioni, Lau · BMJ (2007)
Updated meta-analysis of double-blind randomised placebo-controlled trials of approved anti-obesity drugs lasting one year or longer; 30 trials met inclusion, of which 16 were orlistat trials (n=10,631 participants)
Orlistat reduced weight by 2.9 kg vs placebo (95% CI 2.5 to 3.2 kg) — smaller than sibutramine (4.2 kg) and rimonabant (4.7 kg) in the same analysis
Patients on active drug were significantly more likely to achieve 5% and 10% weight-loss thresholds
In plain English: A median 23% of placebo participants had at least 5% weight loss vs ... 44% taking orlistat (OR, 2.70; 95% CrI, 2.34-3.09; SUCRA, 0.22).
Bayesian network meta-analysis of 28 randomised trials in 29,018 overweight or obese adults comparing the five FDA-approved long-term weight-loss agents
Orlistat: 44% of patients achieved ≥5% weight loss vs a 23% placebo median (OR 2.70, 95% CrI 2.34–3.09), with the lowest SUCRA ranking (0.22) of the five agents
Excess weight loss with orlistat was 2.6 kg vs placebo (95% CrI −3.04 to −2.16), compared with 8.8 kg for phentermine-topiramate and 5.3 kg for liraglutide
In plain English: However, due to the quantitative restrictions, additional high-quality study needs to be conducted to improve the reliability of the results.
Gao Z, Huang M, Wang J, Jia H, Lv P, Zeng J, Ti G. · Medicine (2024)
The results indicated that the orlistat can reduce the fasting blood glucose [relative risk (RR) = -2.18, 95% confidence intervals (CI) (-2.471, -1.886)], as well as the 2 hour postprandial blood glucose [RR = -1.497, 95% CI (-1.811, -1.183)].
Furthermore, it can prevent the impaired glucose tolerance patients to type 2 diabetes mellitus [RR = 0.605, 95% CI (0.462, 0.791)], and reversal the impaired glucose tolerance [RR = 2.092, 95% CI (1.249, 3.503)].
Conclusions In prediabetic people, the orlistat can control weight, reduce the fasting blood glucose and the 2 hour postprandial blood glucose, and then delay the progression of diabetes.
In plain English: From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p<0.001] from randomisation to the end of year 1).
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Year 1: 10.2% (10.3 kg) body-weight loss with orlistat vs 6.1% (6.1 kg) with placebo; least-squares-mean difference 3.9 kg from randomisation (p<0.001)
Year 2: patients continuing orlistat regained on average half as much weight as those switched to placebo (p<0.001); those switched from placebo to orlistat lost a further 0.9 kg vs a mean 2.5 kg regain on continued placebo (p<0.001)
In plain English: These findings support the use of combination pharmacotherapy for comprehensive management of PCOS.
Bo Y, Zhao J, Liu C, Yu T. · BMC women's health (2025)
The combination of standard therapy with GLP-1 receptor agonists significantly reduced BW (MD= -3.44; 95% CI= -6.20 to -0.67), BMI (MD= -2.05; 95% CI= -3.55 to -0.55), and WC (MD= -4.39; 95% CI= -6.75 to -2.02) compared to standard therapy alone.
Orlistat significantly lowered testosterone (SMD= -2.16; 95% CI= -3.84 to -0.48) and increased HDL-C levels (SMD = 0.90; 95% CI = 0.02 to 1.79) compared to placebo.
The combination therapy also reduced HOMA-IR (MD= -1.29; 95% CI= -2.38 to -0.21) and FBG (SMD= -1.80; 95% CI= -3.04 to -0.55) compared to placebo.
In plain English: This review has summarized, side-by-side, the various outcomes of obesity interventions on mental health.
Osborne D, Abdelgadir E. · International journal of obesity (2005) (2026)
Mental health is a critical yet underprioritized element of obesity management.
The current evidence suggests that most weight loss interventions are psychologically safe or beneficial, but long-term data remain limited, particularly for GLP-1 receptor agonists.
Future randomized trials must incorporate mental health as a prespecified outcome, and individualized treatment approaches should integrate psychological support to optimize long-term outcomes.
In plain English: The role of these agents in PCOS should be a high priority for future research.
Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, Li R, Mousa A, Tay CT, Pattuwage L, Teede H, Yildiz BO, Ee C. · Obesity reviews : an official journal of the International Association for the Study of Obesity (2024)
On meta-analysis, no differences were identified between exenatide versus metformin for anthropometric, biochemical hyperandrogenism, and metabolic outcomes, other than lower fasting blood glucose more with metformin than exenatide (MD: 0.10 mmol/L, CI 0.02-0.17, I 2 = 18%, 2 trials).
Orlistat + COCP did not improve metabolic outcomes compared with COCP alone (fasting insulin MD: -8.65 pmol/L, -33.55 to 16.26, I 2 = 67%, 2 trials).
Published data examining the effects of anti-obesity agents in women with PCOS are very limited.
In plain English: After 1 year of treatment, the orlistat group lost 6.2 ± 0.45% (mean ± SEM) of initial body weight vs. 4.3 ± 0.49% in the placebo group (P < 0.001).
Multicentre 57-week randomised double-blind placebo-controlled trial of orlistat 120 mg three times daily in 391 obese adults with type 2 diabetes stable on oral sulfonylureas
Weight loss 6.2 ± 0.45% vs 4.3 ± 0.49% of initial body weight (P < 0.001); twice as many orlistat patients lost ≥5% of body weight (49% vs 23%, P < 0.001)
Significant improvement in glycaemic control — decreases in HbA1c (P < 0.001) and fasting plasma glucose (P < 0.001) — with dosage reductions of oral sulfonylurea (P < 0.01)
In plain English: Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
D'Alessio DA et al. · Diabetes, obesity & metabolism (2026)
This mechanistic framework has driven the development of targeted endoscopic and pharmacological strategies, including the duodenal-jejunal bypass liner, duodenal mucosal resurfacing and various pharmacological interventions.
A common goal of these interventions is to exploit duodenal biology to restore metabolic homeostasis.
This review examines duodenal anatomy and function, the pathological remodelling that takes place in metabolic disease, and provides an overview of the expanding therapeutic landscape that targets this underappreciated organ in the treatment of obesity and T2D.
In plain English: Orlistat interferes with the absorption of many drugs (such as warfarin, amiodarone, ciclosporin and thyroxine as well as fat-soluble vitamins), affecting their bioavailability and effectiveness.
Filippatos, Derdemezis, Gazi, Nakou, Mikhailidis, Elisaf · Drug Safety (2008)
Critical review of orlistat's adverse effects and drug interactions, written in light of the FDA approval of over-the-counter orlistat 60 mg three times daily
Gastrointestinal adverse effects are mild-to-moderate but frequent: oily stools, diarrhoea, abdominal pain and faecal spotting
Documented absorption interactions with warfarin, amiodarone, ciclosporin and thyroxine, as well as with fat-soluble vitamins
In plain English: However, larger, high-quality RCTs with longer follow-up are necessary to confirm its long-term efficacy and safety.
Karimi M, Pourfaraji SMA, Parhizkar Roudsari P, Pirzad S. · Current therapeutic research, clinical and experimental (2026)
Pooled effect sizes were calculated using a random-effects model using weighted mean differences (WMD) with 95% confidence intervals (CI).
The pooled analysis showed that Orlistat significantly improved liver enzymes, with reductions in AST (WMD: -4.01 U/L, 95% CI: -6.05 to -1.97, P = 0.005), ALT (WMD: -8.70 U/L, 95% CI: -16.51 to -0.90, P = 0.036), and GGT (WMD: -7.74 U/L, 95% CI: -14.88 to -0.59, P = 0.04).
It also improved lipid profile by lowering LDL-C (WMD: -5.61 mg/dL, 95% CI: -7.36 to -3.86, P = 0.002) and increasing HDL-C in long-term interventions (≥24 months, WMD: 1.65 mg/dL, 95% CI: 0.95-2.36, P = 0.02).
In plain English: While idiosyncratic liver injury following exposure to orlistat cannot be excluded, it is likely to be extremely rare.
Morris, Lane, Lee, Parks · Obesity Facts (2012)
Integrated analysis of liver function data from randomised orlistat trials in over 10,000 subjects, using summary-level meta-analysis, time-to-event analysis and an FDA eDISH-derived method, prompted by post-marketing reports of possible drug-induced liver injury that led to product-information changes
Pooled odds ratio for treatment-emergent ALT abnormality was 1.09 (95% CI 0.93–1.28); for total bilirubin 1.24 (95% CI 1.03–1.49), partly attributable to longer average exposure to orlistat than placebo
Patient-level display adjusting for regression to the mean and Kaplan-Meier analysis of ALT and bilirubin changes showed no significant difference between orlistat and placebo
In plain English: Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required.
Varra FN et al. · Medicina (Kaunas, Lithuania) (2026)
Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits.
Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial.
However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy.
In plain English: Mean vitamin D levels were significantly reduced compared with baseline (p<0.02) after 1 month of orlistat, despite multivitamin supplementation.
Prospective open-label pilot study of 17 adolescents with BMI above the 95th percentile and at least one obesity-related comorbidity, given orlistat 120 mg three times daily plus a daily multivitamin (vitamin A 5000 IU, D 400 IU, E 300 IU, K 25 µg)
Acute absorption of alpha-tocopherol (vitamin E) was significantly reduced compared with baseline (p<0.001); acute retinol (vitamin A) absorption was not significantly altered
Mean vitamin D levels were significantly reduced versus baseline after 1 month (p<0.02) despite the multivitamin